Figure 2.
Free triiodothyronine (FT3), free thyroxine (FT4), and thyroid‐stimulating hormone (TSH) levels during pembrolizumab treatment. Thyroid hormone replacement therapy was initiated at the administration of the fifth course. FT3 (pg/mL),
FT4 (ng/dL),
TSH (μIU/mL)